Klotho Neurosciences (NASDAQ:KLTO – Get Free Report) and ImmunityBio (NASDAQ:IBRX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Insider & Institutional Ownership
20.1% of Klotho Neurosciences shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 2.0% of Klotho Neurosciences shares are owned by company insiders. Comparatively, 83.4% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings for Klotho Neurosciences and ImmunityBio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Klotho Neurosciences | 0 | 0 | 0 | 0 | 0.00 |
| ImmunityBio | 0 | 1 | 1 | 1 | 3.00 |
Valuation & Earnings
This table compares Klotho Neurosciences and ImmunityBio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Klotho Neurosciences | N/A | N/A | $1.35 million | N/A | N/A |
| ImmunityBio | $7.33 million | 249.00 | -$583.20 million | ($0.92) | -2.85 |
Klotho Neurosciences has higher earnings, but lower revenue than ImmunityBio.
Profitability
This table compares Klotho Neurosciences and ImmunityBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Klotho Neurosciences | N/A | -1.48% | -25.89% |
| ImmunityBio | -8,016.83% | N/A | -110.02% |
Summary
ImmunityBio beats Klotho Neurosciences on 7 of the 11 factors compared between the two stocks.
About Klotho Neurosciences
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Receive News & Ratings for Klotho Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Klotho Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
